ArticleScience advances2020
Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.Frontiers in immunology · 2021Pooled it
- The Effect of Pertussis Vaccination During Pregnancy on the Binding Epitopes and Avidity of Anti-Pertussis Toxin Immunoglobulin G Antibodies in Infants and Their Mothers.The Journal of infectious diseases · 2026Trial
- Article
- Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.Chemical science · 2026Article
- BPZE1 vaccination induces IL-17NPJ vaccines · 2026Article
- The Immunogenicity of Glutaraldehyde Inactivated PTx Is Determined by the Quantity of Neutralizing Epitopes.Vaccines · 2025Article
- Structural basis for neutralizing antibody binding to pertussis toxin.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management.Infection & chemotherapy · 2025Review
- Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy.Frontiers in immunology · 2025Article
- A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis.NPJ vaccines · 2024Article
- Structural Basis for Antibody Neutralization of Pertussis Toxin.bioRxiv : the preprint server for biology · 2024Article
- Immunization with an mRNA DTP vaccine protects against pertussis in rats.Infection and immunity · 2024Article
- Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective againstInfection and immunity · 2024Article
- Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice.NPJ vaccines · 2024Article
- HIV-related immune activation attenuates polyfunctional IgG and memory B-cell responses to Tdap immunization during pregnancy.EBioMedicine · 2024Observational
- BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infection and immunity · 2024Article
- Repeated Bordetella pertussis Infections Are Required to Reprogram Acellular Pertussis Vaccine-Primed Host Responses in the Baboon Model.The Journal of infectious diseases · 2024Article
- Maternal acellular pertussis vaccination in mice impairs cellular immunity to Bordetella pertussis infection in offspring.JCI insight · 2023Article
- Antigen Discovery for Next-Generation Pertussis Vaccines Using Immunoproteomics and Transposon-Directed Insertion Sequencing.The Journal of infectious diseases · 2023Article
- Novel murine model reveals an early role for pertussis toxin in disrupting neonatal immunity toFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Pertussis continues to cause considerable infant mortality world-wide, which could be addressed in part by passive immunization strategies. Antibody hu1B7 is a candidate therapeutic that potently neutralizes pertussis toxin in vitro, prevents leukocytosis in mice and treats established disease in weanling baboons as part of an antibody cocktail. Here, we evaluated the potential for hu1B7 and an extended half-life hu1B7 variant to prevent death, leukocytosis and other clinical symptoms in a newborn baboon model that mimics many aspects of human disease. We administered a single antibody dose to newborn baboons five weeks prior to experimental infection. While all animals were heavily colonized with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.